Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://covid19.nih.gov/

Principal Investigator
Name
Gerd Bobe
Institution
NCI-F, CCR, LCP
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2008-0041
Initial CDAS Request Approval
Sep 12, 2008
Title
Flavonoid intake and the risk of pancreatic cancer in the PLCO Cancer Screening Trial
Summary
Background: In the United States, pancreatic cancer is the fourth most common cause of cancer mortality (approximately 33,400 deaths annually) with a five-year survival rate of 5% (ACS, 2007). Flavonoids and proanthocyanidins are a group of bioactive polyphenols distributed widely in the plant kingdom that are especially enriched in certain fruits and vegetables. Based on the protective effect of flavonoids in cell culture and animal studies, we hypothesize that high dietary flavonoid and proanthocyanidin intake may inhibit exocrine pancreatic cancer development in humans. Method: Intakes of total flavonoids, 6 major flavonoid subgroups, 29 individual flavonoids, proanthocyanidins, 6 proanthocyanidin subgroups, and flavonoid-rich foods will be estimated from the baseline questionnaires of the control and intervention arm (DQX and DHQ) in the PLCO Cancer Screening Trial using the 2007 USDA Flavonoid database and the 2004 Proanthocyanidin database for foods. Hazard ratios and 95% confidence intervals of incident exocrine pancreatic cancer will be estimated within quintiles of energy-adjusted flavonoid intakes at baseline and follow-up. Significance: The current study will grant sufficient power to examine prospectively the association between intakes of total, subgroups, and individual flavonoids and proanthocyanidins and incident pancreatic cancer and, combined with the results for other cohorts (ATBC, NIH-AARP), would provide evidence for cancer-protective effects of flavonoids and/or proanthocyanidins that could be followed up by nutrition intervention studies.
Aims

1. Estimate the intakes of total flavonoids, the 6 major flavonoid subgroups, 29 individual flavonoids, proanthocyanidins, 6 proanthocyanidin subgroups, and flavonoid-rich foods from the baseline questionnaires in the PLCO Cancer Screening Trial. 2. Examine the association between dietary intakes of total flavonoids, the 6 major flavonoid subgroups, 29 individual flavonoids, proanthocyanidins, 6 proanthocyanidin subgroups, and flavonoid-rich foods and development of exocrine primary pancreatic cancer in the PLCO Cancer Screening Trial.

Collaborators

Kevin Dodd (Biometry Research Group, DCP, NCI)
Wen-Yi Huang (OEEB, DCEG, NCI)
Rachael Stolzenberg-Solomon (NEB, DCEG, NCI)
Amy Subar (Applied Research Program, DCCPS, NCI)